Dual incretin agonists, such as tirzepatide (a GLP1R–GIPR agonist), show excellent efficacy for type 2 diabetes and obesity therapy. Research identifies the cells and neurons in the pancreas and brain that are targeted by dual agonists, providing further details on their modes of action.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Campbell, J. E. et al. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications. Cell Metab. 35, 1519–1529 (2023). A review article that discusses mechanisms of action of dual agonists.
Pyke, C. & Knudsen, L. B. The glucagon-like peptide-1 receptor-or not? Endocrinology 154, 4–8 (2013). A news and views article on the pitfalls of GLP1R detection using antibodies.
Ast, J. et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. Nat. Commun. 11, 467 (2020). A research article that details LUXendins, the foundation for daLUXendins described here.
Hartig, S. M. & Cox, A. R. Paracrine signaling in islet function and survival. J. Mol. Med. 98, 451–467 (2020). A review article detailing paracrine circuits that underlie regulated pancreatic islet function and survival.
Willard, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5, e140532 (2020). A research article showing that GIPR–GLP1R imbalance and signal balance are key to dual agonist efficacy.
Zhao, F. et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat. Commun. 13, 1057 (2022). A research article reporting the cryo-EM structure of the non-acylated tirzepatide-bound human GLP1R-Gs complex.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: de Bray, A. et al. Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain. Nat. Metab. https://doi.org/10.1038/s42255-025-01342-6 (2025).
Rights and permissions
About this article
Cite this article
Lighting up targets of dual agonist therapies for diabetes and obesity. Nat Metab 7, 1507–1508 (2025). https://doi.org/10.1038/s42255-025-01346-2
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s42255-025-01346-2
